Related Experiment Video
Updated: May 21, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Current Status of Treg Therapy in Transplantation and Autoimmune Disease
Hongwen Li1, Huimin Zeng2,3
1Department of Dermatovenereology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Abstract:
Regulatory T cells (Tregs) represent a critical subset of T lymphocytes essential for maintaining immune homeostasis. Through diverse molecular mechanisms, Tregs exert potent immunosuppressive effects that preserve self-tolerance and mitigate aberrant immune activation. Dysregulation in Treg frequency or function is closely associated with the development of various immune-mediated disorders. This has prompted extensive preclinical investigations and clinical trials evaluating the therapeutic potential of Tregs in conditions such as graft-versus-host disease, solid organ transplantation, and autoimmune diseases, which have yielded promising outcomes. This review provides a comprehensive overview of current preclinical and clinical applications of Treg-based therapies, including adoptive Treg transfer, low-dose IL-2, and CAR-Treg therapy, and discusses their effectiveness in modulating immune responses across diverse pathological contexts.
Related Concept Videos
Cell-mediated Immune Responses
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Tumor Immunotherapy

